Teijin (3401) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
1 Dec, 2025Executive summary
Adjusted operating income for Q2 FY2025 was ¥13.0 billion, down ¥5.6 billion year-over-year, mainly due to declines in materials and aramid businesses, large-scale maintenance, and structural reforms.
Revenue for the six months ended September 30, 2025, was ¥451,043 million, down 11.1% year-over-year, primarily due to the transfer of the composites business in North America.
Net loss attributable to owners of parent was ¥54,835 million, driven by impairment losses and structural reforms in the aramid business.
The transfer of the composites business in North America and significant impairment losses in aramid (Twaron Business) notably affected results.
Financial highlights
1H FY2025 revenue: ¥451.0 billion (down ¥56.5 billion year-over-year); gross profit decreased to ¥64,508 million.
Adjusted operating income: ¥13.0 billion (down ¥5.6 billion year-over-year); EBITDA: ¥44.4 billion.
Interim loss attributable to owners of parent: ¥54.8 billion; basic EPS of ¥(284.41).
Free cash flow improved to ¥7.7 billion from negative ¥7.5 billion year-over-year; operating cash flow increased to ¥38.9 billion.
Net cash provided by operating activities increased to ¥38,915 million; cash and cash equivalents at period end were ¥110,947 million.
Outlook and guidance
FY2025 annual revenue forecast is ¥860,000 million, a 14.5% decrease year-over-year.
Adjusted operating income forecast is ¥25,000 million, down ¥10,000 million from previous guidance.
Net loss attributable to owners of parent is projected at ¥10,000 million, with basic EPS of ¥(51.85).
Annual dividend per share maintained at ¥50; interim dividend of ¥25/share decided.
Latest events from Teijin
- Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation27 Feb 2026 - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Growth centers on high-value, sustainable solutions and global market expansion.3401
Investor Day 202519 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Profits and revenue fell in Q1 FY2025, but full-year outlook and dividend remain steady.3401
Q1 20265 Aug 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Q1 FY2024 revenue and profit surged, with IT business divestiture and IFRS adoption underway.3401
Q1 202513 Jun 2025 - Impairment losses offset strong 1H growth; asset sales and restructuring support FY2024 outlook.3401
Q2 202513 Jun 2025